NYSE:QGEN

Qiagen (QGEN) Stock Forecast, Price & News

$39.58

-0.78 (-1.93%)

(As of 09/21/2023 ET)

Compare

Today's Range: $39.55
▼
$40.17
50-Day Range: $39.59
▼
$47.22
52-Week Range: $39.55
▼
$51.18

Volume: 1.21 million shs
Average Volume: 1.23 million shs
Market Capitalization: $9.03 billion

P/E Ratio: 26.93
Dividend Yield: N/A
Price Target: $49.50

Qiagen MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 25.0% Upside
$49.50 Price Target
Short Interest: Healthy
1.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.83
Upright™ Environmental Score
News Sentiment: 1.15
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 5.31%
From $2.07 to $2.18 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

189th out of 965 stocks

Biological Products, Except Diagnostic Industry

24th out of 160 stocks

3.3

Analyst's Opinion

Consensus Rating
Qiagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $49.50, Qiagen has a forecasted upside of 25.0% from its current price of $39.59.
Amount of Analyst Coverage
Qiagen has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.70% of the float of Qiagen has been sold short.
Short Interest Ratio / Days to Cover
Qiagen has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Qiagen has recently increased by 14.88%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Qiagen does not currently pay a dividend.
Dividend Growth
Qiagen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Qiagen has received a 69.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pharmacovigilance services", "Clinical research services", and "Biochemical assay kits" products. See details.
Environmental Sustainability
The Environmental Impact score for Qiagen is -0.83.

2.9

News and Social Media Coverage

News Sentiment
Qiagen has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Qiagen this week, compared to 4 articles on an average week.
Search Interest
Only 1 people have searched for QGEN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
3 people have added Qiagen to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Qiagen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Qiagen is held by insiders.
Percentage Held by Institutions
57.99% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Qiagen are expected to grow by 5.31% in the coming year, from $2.07 to $2.18 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Qiagen is 26.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.96.
Price to Earnings Ratio vs. Sector
The P/E ratio of Qiagen is 26.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.79.
Price to Earnings Growth Ratio
Qiagen has a PEG Ratio of 9.77. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Qiagen has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Qiagen (NYSE:QGEN) Stock

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

QGEN Price History

30 days | 90 days | 365 days | Advanced Chart

QGEN Stock News Headlines

September 20, 2023 | americanbankingnews.com

Comparing Qiagen (NYSE:QGEN) & Finch Therapeutics Group (NASDAQ:FNCH)

September 13, 2023 | msn.com

Baird Initiates Coverage of Qiagen (QGEN) with Outperform Recommendation

September 22, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

September 12, 2023 | finance.yahoo.com

QIAGEN's (QGEN) New API Streamlines Access to BKB Data

September 12, 2023 | americanbankingnews.com

Qiagen (NYSE:QGEN) Receives New Coverage from Analysts at Robert W. Baird

September 9, 2023 | msn.com

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

September 4, 2023 | finance.yahoo.com

Qiagen N.V. (NYSE:QGEN) is largely controlled by institutional shareholders who own 82% of the company

August 22, 2023 | markets.businessinsider.com

Berenberg Bank Reaffirms Their Buy Rating on Qiagen (QGEN)

September 22, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 18, 2023 | markets.businessinsider.com

Qiagen (QGEN) Receives a Buy from Citi

August 18, 2023 | markets.businessinsider.com

DZ BANK AG Sticks to Their Buy Rating for Qiagen (QGEN)

August 18, 2023 | markets.businessinsider.com

Qiagen (QGEN) was downgraded to a Hold Rating at Berenberg Bank

August 11, 2023 | markets.businessinsider.com

Kepler Capital Reaffirms Their Hold Rating on Qiagen (QGEN)

August 9, 2023 | seekingalpha.com

Qiagen N.V. 2023 Q2 - Results - Earnings Call Presentation

August 9, 2023 | markets.businessinsider.com

Jefferies Keeps Their Hold Rating on Qiagen (QGEN)